Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: Updated subgroup meta-analyses of overall survival

Japanese Journal of Clinical Oncology

Volumn 40, Issue 5, 2010, Pages 432-441

  Xie, De Rong ^a   Yang, Qiong ^a   Chen, Deng Lin ^a   Jiang, Zhi min ^a   Bi, Zhuo Fei ^a   Ma, Wen ^a   Zhang, Yuan Dong ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Capecitabine; Gemcitabine; Meta analysis; Oxaliplatin; Pancreatic neoplasms

Indexed keywords

CAPECITABINE; CISPLATIN; CYTOTOXIC AGENT; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; PLATINUM COMPLEX;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; HUMAN; KARNOFSKY PERFORMANCE STATUS; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT DURATION; PANCREAS TUMOR; REVIEW; RISK; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; ODDS RATIO; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 77952554897     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp198     Document Type: Article

References (32)

1. Yeo CJ, Yeo TP, Hruban RH, Kern SE, Iacobuzio-Donohue CA, Maitra A, et al. Cancer of the pancreas. In: Devita VT, Jr, Hellman S, Rosenberg SA, editors. Cancer: Principles & Practice of Oncology, 5th edn. Philadelphia, USA: Lippincott Williams & Wilkins, 2005;945.
2. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with GEM as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
3. Cunningham D, Chau I, Stocken D, Davies C, Dunn J, Valle J, et al. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. European Cancer Conference (ECCO 13). Eur J Cancer 2005;3(Suppl):12 (Abstract PS11).
4. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009;27:5513-8.
5. Xie DR, Liang HL, Wang Y, Guo SS, Yang Q. Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone. World J Gastroenterol 2006;12:6973-81.
6. Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008;8:82.
7. Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007;25:2607-15.
8. Banu E, Banu A, Fodor A, Landi B, Rougier P, Chatellier G, et al. Meta-analysis of randomised trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer. Drugs Aging 2007;24:865-79.
9. Bria E, Milella M, Gelibter A, Cuppone F, Pino MS, Ruggeri EM, et al. Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials. Cancer 2007;110:525-33.
10. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of report of randomized clinical trials: is blinding necessary? Controlled Clin Trials 1996;17:1-12.
11. Aurelio T. Assessing the influence of a single study in the meta-anyalysis estimate. Stata Tech Bull 1999;8:15-17.
12. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820-6.
13. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997;315:629-34.
14. Scheithauer W, SchüllB,Ulrich-PurH,SchmidK,RadererM, Haider K, et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol 2003;14:97-104.
15. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for clinical cancer research and the Central European Cooperative Oncology Group. J Clin Oncol 2007;25:2212-7.
16. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002;94:902-10.
17. Wang XY, Ni QX, Jin ML, Li Z, Wu Y, Zhao Y, et al. Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer. Chin J Oncol 2002;24:404-7 (in Chinese).
18. Kulke MH, Niedzwiecki D, Tempero MA, Hollis DR, Mayer RJ. A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALGB 89904). J Clin Oncol 2004;22:4011.
19. Li CP, Chao Y. A prospective randomized trial of gemcitabine alone or gemcitabine + cisplatin in the treatment of metastatic pancreatic cancer. J Clin Oncol 2004;22:140.
20. Viret F, Ychou M, Lepille D, Mineur L, Navarro F, Topart D, et al. Gemcitabine in combination with cisplatin (GP) versus gemcitabine (G) alone in the treatment of locally advanced or metastatic pancreatic cancer: final results of a multicenter randomized phase II study. J Clin Oncol 2004;22:4118.
21. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, SchönekäsH, Rost A, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:3946-52.
22. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, et al. A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: the GIP-1 (Gruppo Italiano Pancreas-GOIM/GISCAD/GOIRC) study. J Clin Oncol 2009;27:4504.
23. Di Costanzo F, Carlini P, Doni L, Massidda B, Mattioli R, Iop A, et al. Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC). Br J Cancer 2005;93:185-9.
24. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002;20:3270-5.
25. Riess H, Helm A, Niedergethmann M, Schmidt-Wolf I, Moik M, Hammer C, et al. A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol 2005;23:4009.
26. Rocha Lima CM, Green MR, Rotche R, Miller WH, Jr, Jeffrey GM, Cisar LA, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22:3776-83.
27. Stathopoulos GP, Syrigos K, Aravantinos G, Polyzos A, Papakotoulas P, Fountzilas G, et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 2006;95:587-92.
28. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509-16.
29. Poplin E, Levy DE, Berlin J, Rothenberg M, Cella D, Mitchell E, et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol 2006;24:LBA4004.
30. Yan ZC, Hong J, Xie G. Observation of therapeutic efficacy of a biweekly regimen of Gemzar plus oxaliplatin for 30 cases with advanced pancreatic cancer. Chin J Clin Oncol 2007;34:322-5 (in Chinese).
31. Boeck S, Hinke A, Wilkowski R, Heinemann V. Analysis of prognostic factors in patients with advanced pancreatic cancer: subgroup analysis of a randomized phase III trial comparing single-agent gemcitabine to the gemcitabine plus cisplatin combination. J Clin Oncol 2005;23:4105.
32. Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ Jr, et al. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J Clin Oncol 2007;25: 146-62.